RKV — Rakovina Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$7.54m
- CA$10.99m
Brief: Rakovina Therapeutics Announces The Closing Of Oversubscribed Private Placement Of $4.9 Million
Brief: Rakovina Therapeutics Appoints David Kideckel As Chief Financial Officer
Brief: Rakovina Therapeutics Announces 2024 Financial Results
Brief: Rakovina Therapeutics Announces Successful Synthesis Of Novel Small-Molecule Drug Candidates Designed Under AI Platform Collaboration
Brief: Rakovina Therapeutics Announces Initial Drug Candidates From Deep Docking Ai Molecule Discovery Platform
Brief: Rakovina Therapeutics Announces $1.5 Million Non-Brokered Private Placement
Brief: Rakovina Therapeutics Announces Strategic Pivot To AI
Brief: Rakovina Therapeutics Appoints New Scientific Advisory Board Member
Brief: Rakovina Therapeutics Announces Q3 2022 Financial Results And Provides Corporate Update
Brief: Rakovina Therapeutics Announces Preclinical Data Presentation At 34Th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
Brief: Rakovina Therapeutics Announces Q1 2022 Results
Brief: Rakovina Therapeutics Presents Preclinical Data On Its Novel KT-3000 Series At 2022 AACR Special Conference On Sarcomas
Brief: Rakovina Therapeutics - Receives Notice Of Allowance For New U.S. Patent Covering KT-2000 Series Parp Inhibitors
Brief: Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results And Provides Corporate Update
Brief: Rakovina Therapeutics Inc Receives European And Canadian Patents On KT-2000 Series PARP-Inhibitors